Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC (RARE)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 12/14 10:00:04 pm
46.01 USD   -2.75%
2014Amid Alibaba fever, reasons for caution in IPO market
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Ultragenyx Pharmaceutical : appoints Dr. Wladimir Hogenhuis as COO

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/19/2018 | 01:07pm CET

Ultragenyx Pharmaceutical (NASDAQ:RARE) has expanded its leadership team with the appointment of Wladimir (Vlad) Hogenhuis, M.D., as Chief Operating Officer (COO), effective September 28. Dr. Hogenhuis will report to Emil D. Kakkis, Chief Executive Officer, and will serve on the Executive Leadership Team.

Dr. Hogenhuis joins Ultragenyx from GlaxoSmithKline, where he most recently served as Senior VP and General Manager, Specialty Franchise.

(c) NNA 2018 LEBANON Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE -0.15% 1480 Delayed Quote.11.91%
ULTRAGENYX PHARMACEUTICAL INC -2.75% 46.01 Delayed Quote.-0.80%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ULTRAGENYX PHARMACEUTICAL
12/07Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita (buros..
AQ
12/06Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita™..
GL
11/15ULTRAGENYX PHARMACEUTICAL : Announces Intent to Submit New Drug Application to U..
AQ
11/14ULTRAGENYX PHARMACEUTICAL INC. : Other Events, Financial Statements and Exhibits..
AQ
11/14ULTRAGENYX PHARMACEUTICAL : Announces Intent to Submit New Drug Application to U..
AQ
11/12ULTRAGENYX PHARMACEUTICAL : to Present at Upcoming Investor Conferences
AQ
11/09ULTRAGENYX PHARMACEUTICAL : to Present at Upcoming Investor Conferences
AQ
11/06ULTRAGENYX PHARMACEUTICAL : Management's Discussion and Analysis of Financial Co..
AQ
11/05ULTRAGENYX PHARMACEUTICAL INC. : Results of Operations and Financial Condition, ..
AQ
11/05ULTRAGENYX : 3Q Earnings Snapshot
AQ
More news
Financials ($)
Sales 2018 49,7 M
EBIT 2018 -376 M
Net income 2018 -202 M
Finance 2018 285 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 41,1x
EV / Sales 2019 20,4x
Capitalization 2 327 M
Chart ULTRAGENYX PHARMACEUTICAL INC
Duration : Period :
Ultragenyx Pharmaceutical Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 70,5 $
Spread / Average Target 53%
EPS Revisions
Managers
NameTitle
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Wladimir Hogenhuis Chief Operating Officer
Shalini Sharp Chief Financial Officer & Executive Vice President
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Sector and Competitors
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC-0.80%2 327
GILEAD SCIENCES-8.47%84 823
VERTEX PHARMACEUTICALS15.72%43 460
REGENERON PHARMACEUTICALS1.39%40 527
GENMAB3.84%9 952
SAREPTA THERAPEUTICS INC114.81%7 987